Tempest Therapeutics
IPOTargeted and Immune-Mediated Cancer Therapies
Public · Brisbane, United States · Founded 2011 · $85.0M raised
- Headquarters
- Brisbane, California
- Employees
- 11–50
- Founded
- 2011
- Business Model
- B2B
- Website
- tempesttx.com
- Total Funding
- $85.0M
- Last Round
- $15.0M Private EquityApr 2022
- Rounds
- 2
- Type
- Public
About
A clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors.
Summary
Tempest Therapeutics is a Biotech company based in Brisbane, United States, founded in 2011. It has raised $85.0M in total across 2 rounds, most recently a $15.0M Private Equity round in Apr 2022. Investors include Jerel Davis, EcoR1 Capital and F-Prime Capital.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...